A valuable ally for cataract extraction in glaucoma patients.
By Albert S. Khouri, MD
Integrating Research Into a Busy Clinical Practice
A discussion of the potential benefits and tips for getting started.
By George R. Reiss, MD
Generic Versus Branded Glaucoma Drugs
Generic medications offer therapeutic benefits for some patients.
By Marcos Reyes, MD, and Lauren Wiggins, MD
Glaucoma Drugs in the Pipeline
Physicians share which coming therapies they are most eager to use in their practices.
By Malik Y. Kahook, MD; Paul L. Kaufman, MD; Robert J. Noecker, MD, MBA; and Nathan M. Radcliffe, MD
The Literature By Kevin Kaplowitz, MD, and Osamah Saeedi, MD
Therapeutically Targeting Disease in Glaucoma
New findings of glaucomatous changes in Schlemm canal cells point to the possibility of directing treatment to restore the function of diseased outflow tissue.
By Mark Johnson, PhD, and W. Daniel Stamer, PhD
Cataract Surgery in High-Risk Glaucoma Patients
Do the risks outweigh the benefits?
By Aaron M. Marble, BS; Bradley P. Roth, MS; and Barbara A. Smit, MD, PhD
Management of Hypotony After Device Implantation By Jeffrey R. SooHoo, MD; Leonard K. Seibold, MD; and Malik Y. Kahook, MD
Stem Cells in Glaucoma Therapy
The next several years should bring advances.
By David I. Green, BS, and Yvonne Ou, MD
New Trends in Medical Therapy for Glaucoma
Drugs and delivery systems in development offer the hope of better options for individualized treatment.
By Sunita Radhakrishnan, MD
Optimizing Refractive Outcomes After Trabeculectomy and Aqueous Shunt Surgery
Patients’ visual outcomes are important but often overlooked.
By Cynthia Mattox, MD
Impact of MIGS on Glaucoma Decision Making
Physicians must strike a balance in the face of complexity.
By Andrew G. Iwach, MD
Point/Counterpoint: Should Patients Share the Cost of MIGS Procedures? By John Berdahl, MD, and Quang H. Nguyen, MD
The Effects of Economic Profiling on Ophthalmic Practice
How payers are guiding patients away from specialists’ offices.
By Ruth D. Williams, MD
Optimizing Angle Surgery With ACT By Shakeel Shareef, MD
The Literature By Helen Kornmann, MD, PhD, and Joseph F. Panarelli, MD
Highlights of the AGS Annual Meeting
The latest research findings from the 25th annual meeting of the American Glaucoma Society, held February 26 to March 1, 2015, in Coronado, California.
By Geoffrey T. Emerick, MD
A Resident Reflects on Clinical Glaucoma Rotation By Anton Kolomeyer, MD, PhD
Evaluating the Anterior Chamber Angle
A combination of techniques can yield a clear picture.
By Robert M. Feldman, MD
When Should I Perform Lens Extraction Alone for the Primary Angle-Closure Suspect? By Nicholas P. Bell, MD and Garry P. Condon, MD
LPI, Iridoplasty, or ECP for Chronic Angle-Closure Glaucoma?
Laser treatment remains a mainstay of management.
By Shan Lin, MD
Lens Extraction in Angle-Closure Glaucoma
Cataract surgery is an effective treatment that saves patients from the complications of trabeculectomy.
By Reay H. Brown, MD
Goniosynechialysis and Chronic Angle-Closure Glaucoma
A safer option for patients with a cataract and uncontrolled glaucoma.
By Marlene R. Moster, MD, and Wanda D. Hu, MD
Filtration Surgery and Primary Angle-Closure Glaucoma
Choose a surgical approach based on the contributing mechanism and stage of the disease.
By Sarwat Salim, MD
Why Are There Not More Pharmacotherapies for Glaucoma?
There is plenty of interest but relatively few drugs in advanced-stage development.
By Gary D. Novack, PhD
The Business of Glaucoma By Steven D. Vold, MD
An analysis of early and recent research.
By Murray Johnstone, MD
Steroid Therapy and IOP
Along with the benefits of intravitreal injections and sustained-release implants comes the risk of steroid-induced ocular hypertension.
By Bradley P. Roth, MS, And Barbara Smit, MD, PhD
Gonioscopy-Assisted Transluminal Trabeculotomy: Blending Tradition With Innovation
The ab interno approach may prove to be the safest and most effective for glaucoma surgery.
By Aaron Barrett, MLS(ASCP), And Craig Chaya, MD
Satisfaction Rates With Electronic Health Records
The reviews are mediocre, but some physicians are enthusiastic.
By Jonathan S. Myers, MD
Selecting Glaucoma Medications
Insurance and other financial considerations
By Jacob T. Wilensky, MD
Point/Counterpoint: Is Cost a Viable Reason to Perform Glaucoma Surgery First? By Thomas Patrianakos, DO; Elizabeth Martin, MD; and Sarwat Salim, MD
Uveal Melanoma Masquerading as Pigment Dispersion Syndrome By Yijie (Brittany) Lin, MD, And Joseph F. Panarelli, MD
The Literature By Dipika B. Joshi, MD, and Tak Yee Tania Tai, MD
Neuroprotection in Glaucoma
Researchers continue to seek strategies and agents independent of IOP lowering that will protect neurons from apoptosis.
By Zakaria Bannur, MD, MSc(MEDICINE); Sushil Vasudevan, MBBS, MSurg(Ophth); Jonathan G. Crowston, FRCOphth, FRANZCO, PhD; and Ivan Goldberg, AM, MBBS, FRANZCO, FRACS
Micropulse Laser Trabeculoplasty After Previous Laser Trabeculoplasty By Tak Yee Tania Tai, MD
Will the Cost of Clinical Trials Quash Change in Glaucoma Treatment?
Financial burden compromises phase 3 trials and prolongs the approval of surgical devices.
By Alan L. Robin, MD
Topical Glaucoma Treatment and the Cornea
Alternative strategies may benefit patients with a compromised ocular surface.
By Adam C. Reynolds, MD